XKEM's Nicosan market $500M in Nigeria alone! read:
"According to Dr. Ramesh C. Pandey, Chairman & CEO of Xechem, "We are working hard to bring NICOSAN(TM) / HEMOXIN(TM) to market initially in Nigeria and subsequently in the United States and other countries. There are approximately 4,000,000 people afflicted with Sickle Cell Disease in Nigeria alone, and development of this product is a major initiative of the Nigerian government, which has shown tremendous support for our efforts. The Nigerian market alone represents potential revenue in excess of $500,000,000 for the company. Xechem was prominently mentioned several times in the state of the union address by the Nigerian President late in 2004."
-from 2/17/05 pr